ONP-302 particles are being developed for the treatment of acute pathologic inflammation resulting from TBI. It is currently unknown whether ONP-302 demonstrates efficacy at dose levels lower than 1 mg/mouse or if efficacy is improved at higher dose levels. Additionally, the efficacy of ONP-302 at inhibiting NETs has not been explored. The goals of the studies proposed here are to determine the optimal dose level of ONP-302 and efficacy at inhibiting NETs. The results of these studies will help guide ONP-302 clinical development by enabling optimal dose selection and determining the utility of assaying NETs from blood as biomarker of pharmacodynamic response.
|Effective start/end date||5/5/21 → 7/31/21|
- Cour Pharmaceutical Development Company, Inc. (Kessler AGMT 5/18/21)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.